# Artificial Intelligence In Precision Medicine Market

> Artificial Intelligence in Precision Medicine Market Research Report By Applications (Drug Discovery and Development, Disease Diagnosis and Prognosis, Personalized Treatment Planning, Biomarker Discovery, Clinical Trial Optimization), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision, Big Data Analytics), By Types of Data (Proteomic Data, Imaging Data, Electronic Health Records, Patient Demographics), By Indication and By Regional - Growth & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 18.4%
- **2025:** USD 6.13 Billion
- **2035:** USD 33.47 Billion
- **Key Players:** Tempus AI, NVIDIA, Microsoft, Alphabet (Google), Illumina, Siemens Healthineers, GE HealthCare, Koninklijke Philips

**Report ID:** MRFR/HC/28181-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** November 16, 2026

**URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-precision-medicine-market-29914

---

## Market Summary

## Artificial Intelligence In Precision Medicine Market Summary

The AI in precision medicine market was valued at USD 6.13 billion in 2025 and is projected to reach USD 7.32 billion in 2026 before climbing to USD 33.47 billion by 2035, a CAGR of 18.4% over 2026–2035. Two catalysts anchor that trajectory. The NIH All of Us Research Program released roughly 245,000 whole genomes to researchers in 2024 [2], and UK Biobank opened whole-genome data on 500,000 participants in late 2023 [3]. Both provide developers in the AI in precision medicine market with population-scale training data.

Advancements in deep learning have allowed models to integrate genomic data with pathology slides and clinical notes, replacing rule-based variant filters, static risk calculators, and manual tumor-board evaluation. Nowadays, high-throughput devices can sequence an entire genome for around $200 in reagent cost [22], down from over $1,000 a decade ago [1]; thus, it's affordable enough to feed them. From a regulatory standpoint, developers are able to update approved algorithms without submitting a new application for each retraining cycle according to the FDA's December 2024 final guidelines on preset change control plans.

In 2025, the North American market will account for 41.5% of the total, due to payer-backed genomic testing and the region's concentration of artificial intelligence developers. China, India, and Japan's national genome programs are the main reasons why the Asia-Pacific area is expanding at a rate of 21.6% CAGR. The speed with which the European Health Data Space transforms disjointed hospital information into valuable training data will determine Europe's growth, which now ranks second [8]. In the next ten years, data accessibility, rather than algorithm quality, will dictate the AI precision medicine business.

## Key Report Takeaways

### • By Technology

- Deep Learning holds a 35.1% share of the AI in precision medicine market in 2025, the largest of any technology.
- Natural Language Processing is the fastest-growing technology at a 20.7% CAGR through 2035
- Context-Aware Processing generated USD 1.32 billion in 2025 as EHR-embedded tools mature.

### • By Component

- Software accounts for a 43.3% share, reflecting subscription delivery and frequent model updates
- Service is the fastest-growing component in the AI in precision medicine market, expanding at a 20.8% CAGR.

### • By Therapeutic Application

- Oncology leads with a 32.6% share, built on established biomarker panels and targeted therapies
- . Respiratory is the fastest-growing application at a 21.4% CAGR, fueled by AI analysis of spirometry and imaging
- . Cardiology generated USD 1.12 billion in 2025 from ECG and imaging-based risk models

### • By Region

- North America leads with a 41.5% share
- Europe generated USD 1.66 billion in 2025
- Asia-Pacific is the fastest-growing region at a 21.6% CAGR

## Market Size and Forecast (2021–2035)

Market estimates for artificial intelligence in precision medicine are based on data from over 350 interviews with hospital informatics directors, pharmaceutical R&D chiefs, and AI suppliers, as well as public financing records, regulatory clearance data, and business disclosures. By comparing sequencing quantities with vendor revenue associated with precision medicine use cases, historical values were reconstructed. We model our forecasts by segment and then compare them to the spending on health IT in each region.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Falling sequencing costs | +3.8% | Global | Long-term (≥4 yr) | [1][22] |
| National biobank and genome programs | +3.4% | North America, Europe, Asia-Pacific | Medium-term (2–4 yr) | [2][3] |
| Rising cancer incidence | +3.0% | Global | Long-term (≥4 yr) | [4] |
| Expanding FDA authorization of AI devices | +2.5% | North America | Short-term (≤2 yr) |   |
| Accelerated compute availability | +2.2% | Global | Short-term (≤2 yr) | [10] |
| AI-enabled drug repurposing funding | +1.6% | North America | Medium-term (2–4 yr) | [9] |

### Falling Sequencing Costs

Sequencing a human genome cost close to USD 100 million in 2001 and now runs below USD 1,000, according to National Human Genome Research Institute tracking [1]. Current high-throughput instruments target roughly USD 200 per genome [22]. Health systems can now sequence entire patient cohorts instead of selected cases, and every additional genome raises the value of models that interpret variants at scale.

### National Biobank and Genome Programs

Governments are funding the training data. The 21st Century Cures Act committed about USD 1.46 billion to All of Us, which released roughly 245,000 whole genomes in 2024 [2]. UK Biobank added whole-genome data for 500,000 participants [3], and India's GenomeIndia project made 10,000 genomes available in January 2025. Each release lowers model-building costs, particularly for academic spin-outs without proprietary cohorts.

### Rising Cancer Incidence

The International Agency for Research on Cancer counted 20 million new cancer cases and 9.7 million deaths in 2022, and projects 35 million cases by 2050 [4]. Molecular profiling already guides cancer therapy choice, so oncology absorbs the largest share of AI spending, and rising incidence widens the pool of patients eligible for tumor sequencing.

### Expanding FDA Authorization of AI Devices

The FDA's public list of AI-enabled [medical devices](https://www.marketresearchfuture.com/reports/medical-devices-market-2869) passed 1,000 authorizations in 2025. A predictable pathway matters for investors: the December 2024 guidance on predetermined change control plans allows manufacturers to pre-specify how a model will be retrained and validated. That reduces the cost of keeping models current as genomic evidence evolves.

### Accelerated Compute Availability

[NVIDIA](https://www.nvidia.com/en-us/industries/healthcare-life-sciences/) reported data center revenue of USD 115.2 billion in fiscal 2025 [10], evidence of how quickly GPU capacity is being built out across hyperscale clouds. Cloud access means mid-sized hospitals and diagnostics labs can train or fine-tune genomic models without on-premises clusters.

### AI-Enabled Drug Repurposing Funding

ARPA-H awarded up to USD 48.3 million in 2024 to the MATRIX project, which uses machine learning to score every approved drug against every known disease [9]. Programs like this create public validation methods that commercial developers in the AI in precision medicine market can build on, and show payers that AI-derived treatment hypotheses can reach clinical testing.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Regulatory compliance burden | −2.1% | Europe, North America | Medium-term (2–4 yr) | [7] |
| Ancestry bias in genomic data | −1.7% | Global | Long-term (≥4 yr) |   |
| Cybersecurity and data breach risk | −1.5% | North America | Short-term (≤2 yr) | [13] |
| Unstructured and siloed clinical data | −1.4% | Global | Medium-term (2–4 yr) | [14] |
| Limited reimbursement pathways | −1.2% | North America, Europe | Medium-term (2–4 yr) |   |

### Regulatory Compliance Burden

The EU AI Act entered into force in August 2024 and classifies most medical AI as high-risk, requiring risk management, data governance and human oversight [7]. Penalties for the most serious violations reach EUR 35 million or 7% of global turnover. Smaller developers face duplicated conformity work under both the AI Act and the Medical Device Regulation, which slows European launches.

### Ancestry Bias in Genomic Data

About 86% of participants in genome-wide association studies were of European ancestry as of 2021. Models trained on such data predict less accurately for African, South Asian and Latin American patients. Health systems serving diverse populations hesitate to deploy tools that may widen outcome gaps, and regulators increasingly ask for subgroup performance evidence before clearance.

### Cybersecurity and Data Breach Risk

The February 2024 ransomware attack on Change Healthcare exposed data on roughly 190 million people, the largest health data breach reported to U.S. regulators [13]. Genomic data cannot be reissued like a password. Hospital security teams now scrutinize every new AI vendor connection, lengthening procurement cycles.

### Unstructured and Siloed Clinical Data

An estimated 80% of clinical information sits in free-text notes, scanned documents and images rather than structured fields. Interoperability rules such as the HTI-1 final rule push toward standardized exchange [14], yet most hospitals still need costly data engineering before any model can run. Integration work often exceeds the cost of the AI software itself.

### Limited Reimbursement Pathways

Only a small fraction of the more than 1,000 FDA-authorized AI devices carries a dedicated payment code. Without reimbursement, hospitals must fund AI from operating budgets or justify it through efficiency gains. That restricts adoption to large academic centers and slows uptake in community settings.

## Opportunities

## Artificial Intelligence In Precision Medicine Market Opportunities

### Population Genomics in Emerging Economies

India, Saudi Arabia and the UAE are building national genome datasets from populations underrepresented in existing reference data. India's GenomeIndia release of 10,000 genomes is a starting point for locally trained variant interpretation tools. Vendors in the AI in precision medicine market that partner early with these programs can secure data access and government procurement.

### Data Licensing and Outcomes-Based Business Models

Clinical-genomic datasets are becoming a revenue line in their own right. Tempus reported 2024 revenue of USD 693.4 million, with a large portion coming from data licensing to pharmaceutical sponsors [11]. Federated networks that let sponsors query de-identified records without moving them open a second model: fees tied to trial enrollment or validated outcomes rather than software seats.

### Drug–Gene Interaction Testing in Primary Care

Embedding pharmacogenomics alerts into prescribing workflows could move precision medicine beyond oncology into everyday care. Common drugs such as clopidogrel and certain antidepressants have well-documented gene–drug interactions. AI tools that combine a patient's genotype with medication history and flag risks at the point of prescribing address a large, underserved use case.

### Multimodal Foundation Models

Models that combine genomics, imaging, pathology and clinical text are moving from research to product. AstraZeneca's MILTON model predicted more than 1,000 diseases from UK Biobank data. Developers that can validate multimodal models for specific clinical decisions will command premium pricing.

### Rare Disease Diagnosis and Repurposing

Roughly 7,000 rare diseases have no approved therapy. Variant-effect predictors such as AlphaMissense, which classified 89% of 71 million possible missense variants [16], shorten diagnostic odysseys. Pairing faster diagnosis with repurposing engines like MATRIX [9] creates an opportunity in orphan indications that larger developers have largely ignored.

## Future Outlook

## Artificial Intelligence In Precision Medicine Market Future Outlook

### Multimodal Foundation Models Become Clinical Infrastructure

By the early 2030s, large models trained jointly on genomes, images and clinical text will become shared infrastructure for the AI in precision medicine market, fine-tuned by smaller vendors for specific decisions. The WHO's 2024 guidance on large multimodal models set out more than 40 recommendations for governments and developers [15], an early sign that regulators expect these systems in routine care. Validation, not model building, will become the main cost.

### Federated Data Platforms Replace Data Transfers

Privacy rules and breach risk will push the industry toward federated learning, where models travel to the data. NVIDIA's January 2025 partnerships with IQVIA, Illumina and Mayo Clinic point to platforms built around this approach [25]. Platform owners controlling linked clinical-genomic records will capture a growing share of the AI in precision medicine market.

### Regulation Shifts from Clearance to Lifecycle Oversight

Regulators are moving from one-time approvals to continuous monitoring. The FDA's January 2025 draft guidance on AI-enabled device software and the EU AI Act's high-risk obligations, applying to medical devices from August 2027 [7], will require post-market performance tracking. Vendors with mature monitoring tools will win procurement decisions.

### Population Genomics Reaches Routine Care

Newborn sequencing pilots such as the Generation Study [24] and national programs in Asia and the Gulf will make genomic data a standard part of the medical record for millions of people. Once a genome is on file, AI tools can reanalyze it repeatedly as evidence improves, shifting revenue from one-off tests toward recurring interpretation services.

## Segment Insights

## Artificial Intelligence In Precision Medicine Market Segmentation

### By Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Deep Learning | 35.1% share (2025) | Non-linear genomic and imaging pattern detection |
| Querying Method | USD 0.98 Billion (2025) | Knowledge-base lookups for drug–gene alerts |
| Natural Language Processing | 20.7% CAGR (2026–2035) | Extraction from unstructured clinical notes |
| Context-Aware Processing | USD 1.32 Billion (2025) | EHR-embedded, patient-specific recommendations |

Deep Learning leads the AI in precision medicine market by technology with a 35.1% share, because convolutional and transformer architectures handle the non-linear patterns in genomic and imaging data that rule-based systems miss. Natural Language Processing grows fastest at a 20.7% CAGR as large language models unlock unstructured notes and pathology reports. Querying Method supports knowledge-base lookups for drug–gene alerts, while Context-Aware Processing tailors outputs to a patient's history inside EHR workflows.

### By Component

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hardware | USD 1.39 Billion (2025) | GPU servers and sequencing-linked compute |
| Software | 43.3% share (2025) | Subscription platforms with frequent model updates |
| Service | 20.8% CAGR (2026–2035) | Integration, validation and compliance support |

Software dominates the AI in precision medicine market by component with a 43.3% share, since cloud delivery lets vendors push model upgrades without hardware refresh cycles. Service is the fastest-growing component at a 20.8% CAGR, reflecting hospitals' need for help with data integration, model validation and regulatory documentation. Hardware remains necessary for training workloads, but spending is shifting toward cloud providers as GPU capacity becomes available on demand.

### By Therapeutic Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| oncology | 32.6% share (2025) | Tumor profiling and targeted therapy selection |
| cardiology | USD 1.12 Billion (2025) | ECG and imaging-based risk prediction |
| neurology | 19.4% CAGR (2026–2035) | Early detection of neurodegeneration |
| respiratory | 21.4% CAGR (2026–2035) | COPD and asthma management from spirometry and imaging |
| others | USD 0.71 Billion (2025) | Retinal imaging and dental diagnostics |

Oncology holds a 32.6% share of the AI in precision medicine market by application, built on established biomarker panels and therapy-matching algorithms. Respiratory grows fastest at a 21.4% CAGR as AI interprets spirometry, CT scans and wearable data for COPD and asthma. Cardiology and neurology follow, detecting arrhythmias and prodromal neurodegeneration. The other category covers ophthalmology, where retinal image analysis is the most mature, and dentistry, where AI-assisted radiograph reading is gaining traction.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025 or CAGR 2026–2035) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.5% share | Oncology genomics, FDA-cleared AI devices, cloud platforms |
| Europe | USD 1.66 Billion | Health data space, cancer screening, academic biobanks |
| Asia-Pacific | 21.6% CAGR | National genome programs, hospital digitization |
| South America | USD 0.29 Billion | Private oncology networks, genomic testing access |
| Middle East and Africa | 4.1% share | National genome programs, smart hospital projects |
| Total | USD 6.13 Billion | — |

North America leads the AI in precision medicine market, while Asia-Pacific posts the fastest growth as national genome programs mature. Europe's trajectory depends on the rollout of shared health data infrastructure, and South America and the Middle East and Africa remain early-stage but are attracting public investment.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 87.4% of region | All of Us data, FDA device pathway, payer genomic coverage |
| Canada | USD 0.22 Billion | Provincial genomics initiatives and research hospitals |
| Mexico | 17.9% CAGR (2026–2035) | Private hospital digitization |

The United States dominates regional spending through a combination of federal data programs, venture capital and a mature reimbursement environment for tumor profiling. The Cancer Moonshot target of cutting cancer death rates by half within 25 years keeps federal research dollars flowing into precision oncology [21]. Canada's single-payer data suits population-level modeling, while Mexico's growth comes from private hospital groups.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 22.5% of region | Hospital Future Act digitization funding |
| UK | USD 0.33 Billion | UK Biobank, NHS AI Diagnostic Fund |
| France | 18.6% CAGR (2026–2035) | France Genomic Medicine Plan 2025 |
| Italy | USD 0.14 Billion | Regional oncology networks |
| Spain | 17.8% CAGR (2026–2035) | National precision medicine strategy |
| Nordic Countries | USD 0.12 Billion | Linked national health registries |
| Russia | 3.2% of region | Domestic AI research centers |
| Rest of Europe | USD 0.20 Billion | EU-funded cancer programs |

Policy shapes how the AI in precision medicine market develops in Europe. Europe's Beating Cancer Plan commits EUR 4 billion to prevention and treatment [20], and the European Health Data Space regulation, in force since March 2025, will allow secondary use of health records for research [8]. In the UK, the NHS AI Diagnostic Fund allocated GBP 21 million to deploy AI imaging tools [19], and the Generation Study plans to sequence 100,000 newborns [24].

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 41.8% of region | Hospital AI adoption, domestic sequencing capacity |
| India | 24.9% CAGR (2026–2035) | GenomeIndia, Ayushman Bharat Digital Mission |
| Japan | USD 0.27 Billion | Whole-genome action plan, aging population |
| South Korea | 21.2% CAGR (2026–2035) | National bio big-data project |
| ASEAN | USD 0.10 Billion | Singapore precision medicine program |
| Rest of Asia-Pacific | 6.8% of region | Australian genomics funding |

China holds the largest share of the regional AI in precision medicine market thanks to domestic sequencing capacity and aggressive hospital AI procurement. India grows fastest from a low base as GenomeIndia data and the Ayushman Bharat Digital Mission's health ID system create the foundation for local model training. Japan's whole-genome analysis plan and South Korea's national bio big-data project add sustained government demand.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.6% of region | Private oncology networks, genomic testing labs |
| Argentina | 16.4% CAGR (2026–2035) | Academic research centers |
| Rest of South America | USD 0.05 Billion | Chile and Colombia hospital digitization |

Brazil anchors regional demand through private oncology chains and laboratories that already offer tumor sequencing. Public systems lag on infrastructure, so most spending comes from private payers and sponsored trials. Argentina's growth is driven by academic research groups participating in international genomic consortia.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | USD 0.08 Billion | Saudi Genome Program, Vision 2030 health transformation |
| UAE | 23.0% CAGR (2026–2035) | Emirati Genome Programme |
| South Africa | 14.2% of region | Academic genomics research |
| Egypt | 15.9% CAGR (2026–2035) | Egypt Genome Project |
| Rest of MEA | USD 0.05 Billion | Donor-funded oncology initiatives |

Gulf states drive regional growth. Saudi Arabia's Genome Program and the UAE's Emirati Genome Programme are sequencing citizens at national scale, creating datasets for diseases common in consanguineous populations. South Africa leads sub-Saharan research, though limited hospital digitization keeps commercial adoption low across most of the continent.

## Competitive Benchmarking

## Competitive Benchmarking

The market for artificial intelligence in precision medicine is quite concentrated. The estimated Herfindahl-Hirschman Index is in the 700s to 900s, and the top five companies control 35 to 42 percent of the market. As a result of their access to confidential clinical genomic data and regulatory approvals, specialized businesses compete with large tech corporations that provide computing and cloud platforms.

| Company | Est. Revenue Share Range | Key Offerings for AI in precision medicine | Strategic Positioning |
| --- | --- | --- | --- |
| Tempus AI | ~8–11% | Genomic profiling, clinical-genomic data licensing, AI diagnostics | Data-driven oncology leader expanding into cardiology |
| NVIDIA | ~7–10% | GPUs, Clara and BioNeMo platforms | Compute and model infrastructure provider |
| Microsoft | ~6–9% | Azure health data services, Nuance clinical AI | Cloud and clinical documentation platform |
| Alphabet (Google) | ~5–8% | Google Cloud Healthcare API, DeepMind research models | Research-led foundation model developer |
| Illumina | ~5–7% | Sequencing systems, DRAGEN secondary analysis | Sequencing-anchored analytics provider |
| Siemens Healthineers | ~4–6% | AI-Rad Companion, imaging AI | Imaging-centric diagnostics partner |
| GE HealthCare | ~3–6% | Edison platform, MIM Software [23] | Imaging and theranostics workflow integrator |
| Koninklijke Philips | ~3–5% | IntelliSpace precision diagnosis tools | Integrated diagnostics and informatics |
| IBM | ~2–4% | Watson-based research analytics, hybrid cloud | Enterprise AI services partner |
| Roche (Foundation Medicine) | ~2–4% | Comprehensive genomic profiling, Navify digital tools | Diagnostics and pharma-integrated player |
| SOPHiA GENETICS | ~1–3% | SOPHiA DDM data-driven medicine platform | Decentralized genomic analytics for labs |

## Recent News & Developments

## Recent News & Developments

- UK Biobank (November 2023): Released whole-genome sequencing data for 500,000 participants, the largest open genomic dataset available for AI model training [3]
- U.S. HHS (December 2023): Finalized the HTI-1 rule, requiring transparency about algorithms used in certified health IT decision support tools [14]
- ARPA-H (February 2024): Awarded up to USD 48.3 million to the MATRIX drug repurposing project, validating AI-driven treatment discovery [9]
- Tempus AI (June 2024): Completed its Nasdaq initial public offering, giving the largest pure-play vendor public-market capital for expansion [11]
- European Union (August 2024): The AI Act entered into force, setting high-risk requirements that will apply to most medical AI tools [7]
- Tempus AI (November 2024): Agreed to acquire Ambry Genetics for about USD 600 million, adding hereditary testing data to its platform [11]
- U.S. FDA (December 2024): Issued final guidance on predetermined change control plans for AI-enabled devices, easing model updates
- NVIDIA (January 2025): Announced healthcare AI partnerships with IQVIA, Illumina, Mayo Clinic and Arc Institute focused on genomics and drug discovery [25]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The AI in precision medicine market covers hardware, software and services that apply deep learning, querying methods, natural language processing and context-aware processing to oncology, cardiology, neurology, respiratory and other therapeutic applications. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 6.13 Billion |
| Market Size in 2035 | USD 33.47 Billion |
| CAGR (2026–2035) | 18.4% |
| Fastest Growing Segments | Respiratory (21.4% CAGR); Service (20.8% CAGR); Natural Language Processing (20.7% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Tempus AI, NVIDIA, Microsoft, Alphabet (Google), Illumina, Siemens Healthineers, GE HealthCare, Koninklijke Philips, IBM, Roche (Foundation Medicine), SOPHiA GENETICS |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What should hospitals check before buying a tool in the AI in precision medicine market?**
A: Ask for subgroup performance data across ancestries and a documented retraining plan. Tools cleared with a predetermined change control plan can be updated without new FDA submissions [6].

**Q: How do federated models change data risk in the AI in precision medicine market?**
A: Federated models train where the data sits, so patient records never leave the hospital. That lowers breach exposure but makes validation slower and more expensive to coordinate [25].

**Q: Which investors are most active in the AI in precision medicine market?**
A: Pharmaceutical companies are the most consistent backers, because they buy clinical-genomic data for trial design. Public listings such as the Tempus AI IPO have also opened capital markets to specialist vendors [11].

**Q: Does the EU AI Act affect U.S. vendors?**
A: Yes, any vendor in the AI in precision medicine market placing a medical AI system on the EU market must meet its high-risk requirements. Obligations for AI embedded in medical devices apply from August 2027 [7].

**Q: Can smaller labs compete in the AI in precision medicine market?**
A: Smaller labs compete by focusing on narrow indications and licensing cloud-based analysis instead of building infrastructure. Platforms such as SOPHiA DDM let them share models without pooling raw data.

**Q: What is the newest clinical use case?**
A: Newborn genome sequencing is the newest frontier for the AI in precision medicine market. Programs such as the Generation Study screen for treatable rare conditions at birth, with AI flagging actionable variants [24].

**Q: How long does a typical hospital deployment take?**
A: Most deployments take 9 to 18 months, with data integration consuming the largest share of that time. Security review of vendor connections has lengthened timelines since the 2024 Change Healthcare breach [13].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-precision-medicine-market-29914*
